Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07527143

Acceptability of Testing DNA Markers in Vaginal Fluid for the Detection of Endometrial Cancer

This study evaluates how women feel about using DNA from a vaginal fluid collection for early detection of endometrial cancer.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Endometrial Carcinoma Endometrial Neoplasms Female Urogenital Diseases Female Urogenital Diseases and Pregnancy Complications Genital Diseases Genital Diseases, Female Genital Neoplasms, Female Neoplasms Neoplasms by Site Urogenital Diseases Urogenital Neoplasms Uterine Diseases Uterine Neoplasms

Age range

45 year and older

Sex eligibility

Female

Study type

Observational

Primary location

Mayo Clinic in Rochester

Rochester, Minnesota, 55905, United States

Location status: Recruiting

Location contact

Clinical Trials Referral Office

CONTACT

855-776-0015

Kelly Gunderson

CONTACT

507-422-1892

Shariska Harrington, MD

PRINCIPAL_INVESTIGATOR

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Self-identified Black individuals ≥ 45 years with an intact uterus
  • Assigned female sex at birth
  • Experience with abnormal uterine or post-menopausal bleeding (defined as vaginal bleeding between periods, heavy vaginal bleeding, vaginal bleeding after menopause, and/or red, brown, or pink colored vaginal discharge after menopause)
  • Willing to participate in a 45-minute virtual interview

Exclusion criteria

  • Previous or current diagnosis of endometrial cancer

Treatment and study plan

Non-Interventional Study

Other

Non-interventional study

Other names: Non-Interventional Observational Study, Noninterventional (Observational) Study

Primary outcomes

  1. Acceptability of vaginal fluid collection for a DNA-based early detection endometrial cancer test

    Time frame: Baseline (30-minute virtual interview)

    Information collected during a 30-minute virtual interview using mostly open-ended questions. The interviews will be transcribed and reviewed by the study team to identity themes and create coding categories. Coding categories will be used to organize the data into subthemes. Results will be reported in aggregate. Aggregate results will be disseminated to participants if they elect to receive them.

Study contacts

Contact information is provided by the study sponsor or research team.

Clinical Trials Referral Office

CONTACT

[email protected]

855-776-0015

Kelly Gunderson

CONTACT

507-422-1892

Sponsors and collaborators

Lead sponsor

Mayo Clinic

Other

Registry information

Important dates

Study start
2026
Primary completion
2027
Study completion
2027
First posted
Apr 14, 2026
Registry last updated
Jul 9, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.